Navigation Links
VCU Massey Cancer Center researchers identify a new class of anti-cancer drugs based on platinum

Researchers at Virginia Commonwealth University's Massey Cancer Center have created a new platinum-based, anti-cancer agent able to overcome acquired drug resistance by first modifying the way it is absorbed into cancer cells and then attacking the DNA of those cancer cells.

The findings may help researchers design a new generation of anti-cancer drugs that selectively target cancer cells, reduce resistance and side effects and expand the range of tumors that can be treated by platinum.

In the Dec. 26 issue of the journal Inorganic Chemistry researchers reported on the design of a new trinuclear platinum compound and demonstrated that its cellular absorption is significantly greater than that of neutral cisplatin, as well as other multi-nuclear platinum compounds. The enhanced uptake into cancer cells takes advantage of weak molecular interactions on the cells' surface. These results underscore the importance of the new compound's "non-covalent" interactions, prior to the attack on DNA. Non-covalent interactions minimize potential side reactions and produce changes in the structure of proteins and DNA, which is different from currently used drugs. This research was selected as the cover article for the print version of the journal, Issue 26.

Researchers compared the cytotoxicity and cellular concentrations of three anti-cancer drugs including the phase II clinical drug, BBR 3464, cisplatin and the new trinuclear platinum compound. In a laboratory model, human ovarian cancer cells were exposed to each drug.

"In platinum antitumor chemistry our objective is to design and develop complexes acting by new mechanisms of action," said Nicholas Farrell, Ph.D., professor and chair in the Department of Chemistry at VCU, and lead author of the study. "Resistance to current drugs is due to poor cellular absorption and an increased ability of the cell to process or repair the damage caused by the chemotherapeutic agent."

"Our novel compou
'"/>

Source:Virginia Commonwealth University


Page: 1 2

Related biology news :

1. Massey Cancer Center researcher helps to identify a piece of the cancer puzzle
2. VCU Massey Cancer Center study shows enzyme linked to spread of breast cancer cells
3. Massey researchers induce cell death in leukemia
4. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
5. Jump-starting T Cells In Skin Cancer
6. Deficient DNA Repair Capacity Associated With Increased Risk Of Breast Cancer
7. Fox Chase Cancer Center scientists identify immune-system mutation
8. Breakthrough Microarray-based Technology for the Study of Cancer
9. Yale Scientists Find MicroRNA Regulates Ras Cancer Gene
10. Fundamental Finding Yields Insight into Stem Cells, Cancer; Opens Door to Drug Discovery
11. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
Post Your Comments:
(Date:2/5/2015)... TRIANGLE PARK, North Carolina , 5. ... sein 35. Jahr als spezialisiertes Logistikunternehmen und ... Position als einzige klinische Logistikfirma (Clinical Logistics ... Die Kernbotschaft der neuen Kampagne lautet ... und Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... SAN FRANCISCO , January 28, 2015 ... Camera Market Analysis, Size And Segment Forecasts To 2020 ... The global IR camera market is expected to reach ... study by Grand View Research, Inc. IR cameras help ... injuries, and are expected to witness surging demand in ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced ... Overview" report to their offering. , ... an individual is who she/he is claiming to be, and ... person,s unique physical characteristics, such as fingerprint, hand or palm ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... so indelibly that their children are affected. History ... starvation, whose children experience altered physiology. Now ... University have found an instance of animals passing ... to their offspring. That information comes not through ...
... mapping how proteins interact with each other, developed at ... the design of new drugs for diseases such as ... acids, the Salk scientists determine the detailed molecular structure ... that turns it on. The switch--corticotrophin releasing factor type ...
... 29 November 2013 The American Association for the Advancement ... Science Policy Programme at EMBO, to its 2013 class of ... upon AAAS members by their peers and acknowledges contributions that ... been recognized by AAAS for her work looking at the ...
Cached Biology News:Mice can inherit learned sensitivity to a smell 2Mice can inherit learned sensitivity to a smell 3Salk scientists crack riddle of important drug target 2Salk scientists crack riddle of important drug target 3
(Date:2/27/2015)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... announced that it will be presenting at CALBIO 2015 ... nd at 3pm PST. Patrick Lucy, chief business officer ... current state of the biosimilar industry landscape entitled ... For more information on CALBIO 2015 and The ...
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 Cytokinetics, ... forces on February 28 with patients and health care ... awareness for Rare Disease Day®. Rare Disease Day ... and calling attention to the special challenges faced by ... them. , “Cytokinetics is proud to stand alongside patients ...
(Date:2/27/2015)... , Feb. 27, 2015   PureTech , a ... and commercializing disruptive products and technologies in the healthcare ... , former CEO and Member of the Board of ... "It,s has been a pleasure to know ... that we will be working together more closely now," ...
(Date:2/26/2015)... 26, 2015 On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured a ... Genewiz Inc. in excess of $10 million. The jury ... secrets, and that it improperly hired one or more ... motions for judgment notwithstanding the verdict, a new trial, ...
Breaking Biology Technology:Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... and VANCOUVER, Feb. 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ... survival rate from a Phase 1/2 clinical trial of ... of advanced non-small cell lung cancer (NSCLC). At two ... first-line chemotherapy were alive. OncoGenex has previously reported a ...
... introduction to the benefits of Shape Memory Alloys. The Kit is a ... a comprehensive manual, and easy to follow demonstrations on the morphing abilities ... ... -- Imagine a future where the only tool in an auto body ...
... HUNTINGTON BEACH, California and AMSTERDAM, February 4 ... diagnostics, today announced that,its signature breast cancer ... of,care for all eligible early stage breast ... Leeuwenhoek Hospital (NKI-AVL). The NKI-AVL,believes MammaPrint provides ...
Cached Biology Technology:OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer 2OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer 3OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer 4OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer 5Re-Shaping the Future with Shape Memory Alloys - SMA Starter Kit 2Re-Shaping the Future with Shape Memory Alloys - SMA Starter Kit 3Agendia's Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL 2
... The electrophoretic mobility shift assay (EMSA) ... interactions. Often referred to as gel shift ... on the principle that when subjected to ... a DNA-protein complex. The Pierce LightShift Chemiluminescent ...
... Lab Quantas unique combination of Coulter ... resolution capabilities and accurate cell counting. ... wavelengths, including UV, allowing flexible fluorochrome ... applications typically only achievable with larger, ...
... Genome-pULSe Kit delivers a novel procedure for ... labeling of whole genome DNA from small ... provide a quick and highly reproducible amplification ... consists of a REPLI-g Mini Kit module ...
... using PULSin may be superior to transfection ... traditional transfection, with PULSin you can study ... time course of proteins in cells. Likewise, ... information than traditional RNA interference experiments. ...
Biology Products: